Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02933528 · ClinicalTrials.gov registry record · Phase 2
Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS
A Phase 2 study of Psoriasis, sponsored by Sun Pharmaceutical Industries.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT02933528: Completed Phase 2 study of Psoriasis, sponsored by Sun Pharmaceutical Industries.
NCT02933528 is a Phase 2 study of Psoriasis that has completed, run by Sun Pharmaceutical Industries. The registered enrollment target is 24 participants, below the 489-participant average among 125 other Psoriasis trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02933528, a Phase 2 study of Psoriasis, has completed, sponsored by Sun Pharmaceutical Industries.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment with DSXS .
Primary Outcome
Hypothalamic Pituitary Adrenal (HPA) Axis Response to stimulation
Conditions Studied
Interventions
- DRUG DSXS Topical product
Study Locations (1)
New York
- Taro Pharmaceuticals USA, Inc. - Hawthorne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2016-07-11 |
| Est. Completion | 2017-11-27 |
| Phase | Phase 2 |
What the finished NCT02933528 record still lists
NCT02933528 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 489-participant average among 125 other Psoriasis trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which DSXS Topical product is the first listed.
NCT02933528 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT02933528 about?
NCT02933528 is a clinical study titled "Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS". An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment with DSXS .
What is the current status of trial NCT02933528?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2016-07-11. Estimated completion is 2017-11-27.
What conditions does trial NCT02933528 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT02933528?
The interventions under investigation include: DSXS Topical product (DRUG).
Who is sponsoring clinical trial NCT02933528?
This trial is sponsored by Sun Pharmaceutical Industries, which has 48 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02933528 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02933528's enrollment target sits among peer trials
24 105th of 125 higher than 20 of 125 other Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study in Participants With Moderate to Severe Psoriasis
COMPLETED · Phase 2
-
Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis
COMPLETED · Phase 2
-
A Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate)
COMPLETED · Phase 2
-
Etanercept With Tacrolimus for Psoriasis
COMPLETED · Phase 2
-
A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis
COMPLETED · Phase 2
-
A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI